Global Smoking Cessation and Nicotine De-Addiction Market is expected to grow with the CAGR of 27.1% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.
Global smoking cessation and nicotine de-addiction market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.
The major players dealing in global smoking cessation and nicotine de-addiction market are introducing strong range of product portfolio. This helped company to maximize the sales with enhanced product portfolio.to expand the global presence of the companies in the market, for instance, in February 2020, Strides Pharma Science Limited, the parent firm of Strides Product Private Limited, joined the industry with the launch of two over - the-counter (OTC) drugs for smoking cessation and joint pain relief. This will allow the company to grow its market and will also encourage the company to increase its consumer base.
Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for smoking cessation and nicotine de-addiction through expanded production range
Imperial Brands, is the dominating player in global smoking cessation and nicotine de-addiction market. The other key players existing in the market includes Cipla Inc., Johnson & Johnson Services, Inc., Takeda Consumer Healthcare Company Limited, Alkalon A/S, 22nd Century Group, Inc., GlaxoSmithKline plc., Japan Tobacco Inc., British American Tobacco, Perrigo Company plc, Fertin Pharma, Cambrex Corporation, Dr. Reddy’s Laboratories Ltd., Pfizer Inc. and Strides Pharma Science Limited.
Imperial Brands is headquartered in Bristol, U.K. The company is engaged in providing fast moving consumer goods borne out of a strong tobacco. The business segment of the company is tobacco & NGP and distribution in which the tobacco & NGP are the market focused segment of the market
The company has wide presence in, U.K., Germany, France, U.S. 1213509 B.C. Limited (Canada), 800 JR Cigar Inc (U.S.), Altadis S.A.U.(Spain), Athena IPVermogensverwaltungs GmbH (Germany), Coralma International SAS (France)are some of the subsidiaries of the company.
22ND Century Group, Inc
22ND Century Group, Inc is a headquartered in New York, U.S. The company is engaged in reducing nicotine in tobacco and making new hemp/cannabis plant for reducing the harm caused by smoking. The products included in the company are Spectrum, Moonlight and VLN out of which Spectrum, Moonlight and VLN are market focused categories
The company has wide presence in U.S. and Botanical Genetics, LLC (U.S.), Goodrich Tobacco Company, LLC (U.S.), Hercules Pharmaceuticals B.V. (U.S.), 22nd Century Limited LLC (U.S.) and NASCO Products, LLC (U.S.) are some of the subsidiaries of the company
Pfizer Inc has headquartered in New York, U.S. The company focus on discovery, development and manufacture of health care products, including innovative medicines and vaccines. The company deals in the business development of innovative health (IH), essential health (EH) out of which Innovative Health (IH) are market focussed business segments.
The company is having a wide geographical presence at North America, South America, Europe, Asia-Pacific, Middle East and Africa, Americas, Asia-Pacific. Agouron Pharmaceuticals, LLC (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC(U.S.) and G. D. Searle & Co. Limited (U.K.)are some of the subsidiaries of the company.